Plain-English translation of NCT07200830 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing Lutetium 177Lu PSMA radioligand therapy, a radioactive drug designed to target prostate cancer cells that have stopped responding to standard hormone treatments. The study compares two different ways of giving this medication: one where the dose stays the same every time, and another where the dose is adjusted based on how well your cancer is responding. Researchers want to see which approach helps people live longer and feel better.
Advanced prostate cancer often stops responding to standard hormone therapies, leaving patients with limited options. This study exists to find out whether personalizing the dose of this new radioactive treatment based on early response could help more patients and reduce side effects.
You likely qualify if…
You likely don't qualify if…
You will start with an initial screening phase where you receive two doses of the treatment 6 weeks apart and have your PSA levels checked. If your cancer responds well enough, you will then be randomly assigned to receive either the standard fixed dose or the personalized adjusted-dose schedule for up to 4 more treatment cycles. Throughout the study, you will have regular blood tests, imaging scans (CT and bone scans), and quality-of-life questionnaires over approximately 30 months to see how the treatment is working and how you are feeling.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States